Related Experiment Video

Updated: Jul 14, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic

John Nemunaitis1, Laura Stanbery1, Adam Walter1,2

  • 1Gradalis, Inc, Dallas, TX, United States.

Oncology Reviews
|October 6, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
homologous recombinationimmune responseimmunotherapyneoantigenovarian cancer

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.7K

Related Experiment Videos

Last Updated: Jul 14, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Crossing Over01:30

Crossing Over

4.4K
Crossing over is the exchange of genetic information between homologous chromosomes during prophase I of meiosis I. Genetic recombination gives rise to allelic diversity in the newly formed daughter cells. In humans, crossing over produces genetically distinct haploid egg and sperm cells that undergo fertilization to produce unique offspring. Before cell division starts, the germ cell’s chromosome(s) undergo duplication in the S phase of the cell cycle. As the cells enter prophase I,...
4.4K

Articles linked to this work by shared authors, journal, and citation graph.

Survivability in patients with rare sigmoid colon adenocarcinoma variants: exploring the influence of rural-urban continuum codes and social determinants of health in the USA.

Cancer causes & control : CCC·2026

In Vivo Assessment of dbDNA GNEwt/bi-shRNA-GNEM743T Lipoplex for GNE Myopathy: Improved Potency and Safety.

The journal of gene medicine·2026

Proof-of-concept study for the detection of somatic structural variant driver alterations using HiFi long-read sequencing in a pediatric leukemia cohort.

NPJ genomic medicine·2026

Preclinical assessment of GNEwt/bi-shRNA-GNEM743T lipoplex product development for GNE myopathy.

Future science OA·2026

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

JCO precision oncology·2026

Accurate somatic small variant discovery for multiple sequencing technologies with DeepSomatic.

Nature biotechnology·2025

Non-coding RNAs as predictive factors of oncological outcomes in plasma cell myeloma.

Oncology reviews·2026

Acidosis and the role of nanotechnology in mitigating cancer progression.

Oncology reviews·2026

Assessing real-world evidence utilization in oncology health technology assessments: insights from external control-arm studies.

Oncology reviews·2026

Recent advances in photoacoustic-ultrasound dual-modality fusion imaging for functional visualization of the superficial tumor microenvironment.

Oncology reviews·2026

Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatment.

Oncology reviews·2026

Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.

Oncology reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us